GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases

NCT03765983 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

17

Enrollment

OTHER

Sponsor class

Stopped participants are no longer being examined or receiving intervention

Conditions

Breast Cancer

Interventions

DRUG: Trastuzumab
DRUG: GDC-0084

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]